Regenxbio (RGNX) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Regenxbio (NASDAQ:RGNX) from a hold rating to a buy rating in a report issued on Monday, February 4th.

Several other analysts also recently issued reports on RGNX. Raymond James reissued a buy rating on shares of Regenxbio in a research report on Monday, October 29th. BidaskClub raised shares of Regenxbio from a hold rating to a buy rating in a research report on Saturday, November 3rd. Zacks Investment Research upgraded Regenxbio from a hold rating to a buy rating and set a $78.00 price objective on the stock in a research note on Wednesday, November 7th. Bank of America raised their price objective on Regenxbio from $76.00 to $84.00 and gave the company a neutral rating in a research note on Thursday, November 8th. Finally, Leerink Swann began coverage on Regenxbio in a research note on Tuesday, November 27th. They set an underperform rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $77.97.

NASDAQ RGNX opened at $53.86 on Monday. Regenxbio has a 12-month low of $26.80 and a 12-month high of $85.10. The firm has a market capitalization of $1.67 billion, a P/E ratio of 22.63 and a beta of 0.41.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.43. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. Equities analysts forecast that Regenxbio will post -3.16 earnings per share for the current year.

In other news, CEO Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction on Friday, February 15th. The stock was sold at an average price of $47.29, for a total transaction of $709,350.00. Following the sale, the chief executive officer now directly owns 261,000 shares in the company, valued at approximately $12,342,690. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction on Monday, December 17th. The stock was sold at an average price of $46.35, for a total value of $347,625.00. Following the sale, the chief financial officer now owns 125,683 shares in the company, valued at $5,825,407.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 106,632 shares of company stock worth $5,134,947. Company insiders own 16.90% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Regenxbio by 2.1% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,192 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 225 shares during the period. Piedmont Investment Advisors Inc. raised its stake in shares of Regenxbio by 5.8% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 7,198 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 395 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Regenxbio by 8.0% during the 4th quarter. Public Employees Retirement System of Ohio now owns 5,364 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 398 shares during the period. New York State Teachers Retirement System raised its stake in shares of Regenxbio by 3.6% during the 4th quarter. New York State Teachers Retirement System now owns 12,649 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 438 shares during the period. Finally, State of Alaska Department of Revenue raised its stake in shares of Regenxbio by 5.0% during the 4th quarter. State of Alaska Department of Revenue now owns 10,065 shares of the biotechnology company’s stock worth $422,000 after purchasing an additional 475 shares during the period. Institutional investors own 81.48% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: Investing in Dividend Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.